ClinicalTrials.gg
Active, not recruitingNCT04661007J-MINDUpdated Oct 21, 2026Results posted

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

A Phase 1/2 interventional study of tafasitamab and lenalidomide in Non Hodgkins Lymphoma and Diffuse Large B-cell Lymphoma, sponsored by Incyte Biosciences Japan GK. Active, not recruiting at 23 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Incyte Biosciences Japan GK (part of Incyte Corporation) · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 21, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing tafasitamab in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 9 under way, 2 of them phase 3. tafasitamab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
6th of 12
72 · median 69
Started
2020
the only one that year
Phase 1/2
2 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
1 of 12
Incyte Biosciences Japan GK

Among the 12 studies testing tafasitamab in Lymphoma, Large B-Cell, Diffuse, this one is the 6th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 4th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

3 of the 12 studies testing tafasitamab in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tafasitamab

tafasitamab: first FDA approval 2020 (MONJUVI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tafasitamab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.

03

Conditions studied

  • Non Hodgkins Lymphoma
  • Diffuse Large B-cell Lymphoma

Browse trials for

Keywords

  • INCMOR00208
  • tafasitamab
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's enrollment of 72 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Incyte Biosciences Japan GK is the lead sponsor of 6 studies on the registry; none are open to participants now.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Group 1 only: -proven participants with NHL of DLBCL, FL or MZL.
  • Groups 3, 4a and 5 only: Biopsy-proven participants with relapsed or refractory DLBCL.
  • Groups 2 and 6 only: Biopsy-proven participants with DLBCL and another select lymphoid neoplasms.
  • Participants must have at least 1 bi-dimensionally .
  • performance status of 0 to 2.
  • Participants with protocol defined laboratory criteria at screening as defined in the protocol.
  • Group 1 only:

Received at least 1 previous systemic therapy line for the treatment of NHL. At least 1 previous therapy line must have included a CD20-targeted therapy (eg, RTX).

  • Groups 2, 3, 4a and 6 only:

Received at least 1, but no more than 3, previous systemic therapy lines for the treatment of DLBCL. At least 1 previous therapy line must have included a CD20-targeted therapy (eg, RTX).

  • Group 5 only: Participants must have:

    1. Untreated DLBCL.
    2. Ann Arbor Stage III to IV.
    3. IPI status of 3 to 5 or age-adjusted IPI 2-3 (in Group 5 only).
    4. Appropriate candidate for R-CHOP.
    5. of ≥ 50%, assessed by echocardiography.
  • Willingness to avoid pregnancy or fathering children.
  • In the opinion of investigator, the participant must:

    1. Not have a history of noncompliance in relation to medical regimens or be considered potentially unreliable and/or uncooperative.
    2. Be able to understand the reason for complying with the special conditions of the pregnancy prevention risk management plan and give written acknowledgement of this.

Exclusion criteria

Exclusion Criteria:

  • Any other histological type of lymphoma.
  • History of prior non-hematologic .
  • Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
  • Participants with known positive test result for , and .
  • Known seropositive for or history of active viral infection with .
  • Known active bacterial, viral, fungal, mycobacterial, or other infection at screening.
  • Known CNS lymphoma involvement - present or past medical history.
  • History or evidence of cardiovascular, CNS and/or other systemic disease that would in the investigator's opinion preclude participation in the study or compromise the participant's ability to give .
  • History or evidence of rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  • History or evidence of interstitial lung disease.
  • Vaccination with within 21 days prior to study treatment (Note: throughout the study treatment period and at least 6 months after end of treatment, vaccination with live vaccines should be avoided).
  • Major surgery within up to 30 days prior to signing the ICF, unless the participant is recovered at the time of signing the ICF.
  • Any anticancer and/or therapy within 14 days prior to the start of Cycle 1.
  • Groups 2, 3, 4a, 5 and 6 only: Gastrointestinal abnormalities including the inability to take oral study treatment, requiring IV alimentation, or prior surgical procedure affecting absorption.
  • Pregnancy or lactation.
  • Groups 2, 3, 5 and 6 only: Participants who have history of deep venous thrombosis/embolism, threatening thromboembolism, stroke or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period if required
  • Group 4a only: Use or expected use during the study of any restricted medications, including potent inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the date of study treatment administration
  • Groups 1, 3, 4a and 6 only: Participants who have:

    1. Not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy, or other lymphoma-specific therapy within the 14 days prior to Day 1 dosing.
    2. In the opinion of the investigator, not recovered sufficiently from the adverse toxic effects of prior therapies.
    3. Groups 1, 3 and 4a only: Previous treatment with CD19-targeted therapy (eg, CD19-CAR-T therapies, other CD19 mAbs including bispecific and ADCs).

      Groups 2 and 6 only: Previous treatment with tafasitamab. Note: Participants in Groups 2 and 6 who have received previous CD19 directed therapy (other than tafasitamab) must have CD19-positive lymphoma confirmed by a taken after completing the prior CD19-targeted therapy.

    4. Groups 2, 3 and 6 only: Been previously treated with IMiDs (eg, thalidomide or LEN).
    5. Group 4a only: Been previously treated with selective PI3Kδ or pan-PI3K inhibitors (eg, idelalisib, copanlisib, duvelisib) and/or Bruton's tyrosine kinase inhibitors (eg, ibrutinib).
    6. A history of to compounds of similar biological or chemical composition to tafasitamab, IMiDs, and/or the contained in the study treatment formulations (citric acid monohydrate, polysorbate 20, sodium citrate dehydrate and trehalose dihydrate).
    7. Undergone within the period ≤ 3 months before the signing of the ICF. Participants who have a more distant history of ASCT must exhibit full hematological recovery before enrolment into the study.
    8. Undergone previous allogenic stem cell transplantation.
    9. Concurrent treatment other anticancer or experimental treatments.
  • Group 5 only: Participants who have:

    1. A history of radiation therapy to ≥ 25% of the bone marrow for other diseases or history of anthracycline therapy.
    2. A history of hypersensitivity or to any component of R-CHOP, LEN, or compounds of similar biological or chemical composition as tafasitamab and/or the excipients contained in the study treatment formulations or R-CHOP.
    3. Contraindication to any of the individual components of R-CHOP.
    4. Any anticancer and/or investigational therapy within 30 days prior to the start of Cycle 1, except for permitted prephase treatment defined below.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Part 1 : tafasitimab monotherapy

    Dose-finding to evaluate the safety and tolerability and to determine the RP2Ds of single-agent tafasitamab in Japanese participants with NHL. Part 1 consists of 1 group (Group 1) to evaluate weight-based doses of tafasitamab.

    Drug: tafasitamab

  • Experimental
    Part 2 : tafasitamab combination therapy

    tafasitamab will be combined with lenalidomide (Group 3) or parsaclisib (Group 4a) in R/R DLBCL participants or lenalidomide plus R-CHOP (Group 5) in previously untreated DLBCL participants. Modified tafasitamab dosing when combined with lenalidomide (Group 2) in participants with R/R DLBCL will be evaluated to determine the recommended clinical dose. The dose of tafasitamab will be based on the weight-based RP2D that is deemed safe and tolerable in Part 1.

    Drug: tafasitamab · Drug: lenalidomide · Drug: parsaclisib · Drug: R-CHOP

  • Experimental
    Part 3 : Dose Expansion of tafasitamab +parsaclisib

    tafasitamab in combination with parsaclisib will be further evaluated in Group 4b at RP2D determined in Part 2

    Drug: tafasitamab · Drug: parsaclisib

  • Experimental
    Part 4: tafasitamab combination therapy

    tafasitamiab in combination with lenalidomide will be further evaluated in Group 6 at RP2D determined in Part 2.

    Drug: tafasitamab · Drug: lenalidomide

Interventions

  • tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.

    Also known as: INCMOR00208, MOR00208, Xmab5574

  • lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.

  • parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.

  • DrugR-CHOP

    R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.

07

What researchers measure

Primary outcomes

  1. Phase 1, Parts 1 and 2; Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose.

    Time frame: up to 1066 days

  2. Phase 1, Parts 1 and 2; Number of Participants With Any ≥Grade 3 TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 1066 days

  3. Phase 1, Part 1 and Part 2 (Groups 3, 4a, and 5); Number of Participants With Any Dose-limiting Toxicity (DLT)

    A DLT was defined as the occurrence of any protocol-defined toxicity occurring up to and including Day 28 (Day 21 in Group 5 only), except those with a clear alternative explanation.

    Time frame: up to 28 days

  4. Phase 2, Part 4: Objective Response (OR) as Determined by an Independent Review Committee (IRC) According to Lugano Criteria

    OR=percentage of participants with a complete response/complete metabolic response (CR/CMR) or partial response/partial metabolic response (PR/PMR). CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 centimeters (cm) in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

    Time frame: up to 723 days

Secondary outcomes

  1. Phase 1, Parts 1 and 2; Cmax of Tafasitamab

    Cmax was defined as the maximum observed plasma concentration of tafasitamab. Samples were collected as follows: Groups 1, 3, and 4a: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours post-infusion (PI). Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 4, 8, 15, and 22, preinfusion; 1 hour PI. Cycles 2 and 3 Days 1, 22, preinfusion and 1 hour PI. Cycle 4 and beyond every 4 cycles (8, 12, etc.) Day 1, preinfusion. Safety follow-up/end of study visit, untimed sample. Group 2: Cycle 1 Days 1, 4, 8, and 15, preinfusion, 30 min PI. Cycles 2 and 3 Days 1 and 15, preinfusion and 30 min PI. Cycle 4-12 (every other cycle, i.e., Cycle 4, 6, 8, 12) Day 1, preinfusion and 30 min PI. Cycle 12 Day 28 and end of treatment, untimed sample. Group 5: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours PI. Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 8 and 15, preinfusion and 1 hour PI. Cycles 2 and 3-6 Day 1, preinfusion and 1 hour PI.

    Time frame: Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment

  2. Phase 1, Parts 1 and 2; Cmin of Tafasitamab

    Cmin was defined as the minimum observed plasma concentration of tafasitamab. Samples were collected as follows: Groups 1, 3, and 4a: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours post-infusion (PI). Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 4, 8, 15, and 22, preinfusion; 1 hour PI. Cycles 2 and 3 Days 1, 22, preinfusion and 1 hour PI. Cycle 4 and beyond every 4 cycles (8, 12, etc.) Day 1, preinfusion. Safety follow-up/end of study visit, untimed sample. Group 2: Cycle 1 Days 1, 4, 8, and 15, preinfusion, 30 min PI. Cycles 2 and 3 Days 1 and 15, preinfusion and 30 min PI. Cycle 4-12 (every other cycle, i.e., Cycle 4, 6, 8, 12) Day 1, preinfusion and 30 min PI. Cycle 12 Day 28 and end of treatment, untimed sample. Group 5: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours PI. Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 8 and 15, preinfusion and 1 hour PI. Cycles 2 and 3-6 Day 1, preinfusion and 1 hour PI.

    Time frame: Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment

  3. Phase 2, Part 4; Cmax of Tafasitamab

    Cmax was defined as the maximum observed plasma concentration of tafasitamab.

    Time frame: Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample

  4. Phase 2, Part 4; Cmin of Tafasitamab

    Cmin was defined as the minimum observed plasma concentration of tafasitamab.

    Time frame: Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample

  5. Phase 1, Part 2: Percentage of Participants With the Indicated Response Per Investigator Assessment of Response According to the Lugano Criteria

    CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

    Time frame: up to approximately 6 years

  6. Phase 1, Part 2: Percent Reduction in the Sum of the Products of Perpendicular Diameters for Multiple Lesions in up to 6 Target Measurable Nodes/Extranodal Sites Assessed by Computed Tomography as Per Investigator Assessment of Lugano Criteria Response

    The sum of the products of the longest perpendicular diameters (SPD) was calculated by summing the products of the two longest perpendicular diameters for each target lesion or any extranodal lesion. Percent reduction in SPD from baseline in up to 6 target measurable nodes and extranodal sites assessed by computed tomography as per investigator assessment of response according to the Lugano criteria was calculated per assessment, and the highest reduction was analyzed.

    Time frame: up to approximately 6 years

  7. Phase 2, Part 4: Complete Response (CR) as Determined by an IRC According to Lugano Criteria

    CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative.

    Time frame: up to approximately 6 years

  8. Phase 2, Part 4: Kaplan-Meier Estimate of Duration of Response (DOR) as Determined by an IRC According to Lugano Criteria

    DOR was defined as the time from the first documented CR/CMR or PR/PMR as determined by an IRC according to the Lugano criteria until the date of the first documented disease progression or death due to any cause, whichever occurred first. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

    Time frame: up to approximately 6 years

  9. Phase 2, Part 4: Kaplan-Meier Estimate of Progression-free Survival (PFS) as Determined by an IRC

    PFS was defined as the time from the date of the first dose of study treatment until the first documented disease progression as determined by an IRC according to the Lugano criteria or death due to any cause, whichever occurred first. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

    Time frame: up to approximately 6 years

  10. Phase 2, Part 4: Kaplan-Meier Estimate of Overall Survival

    Overall survival was defined as defined as the time from the first dose of study treatment until death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

    Time frame: up to approximately 6 years

  11. Phase 2, Part 4: OR as as Per Investigator Assessment of Response According to the Lugano Criteria

    OR=percentage of participants with a CR/CMR or PR/PMR. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

    Time frame: up to approximately 6 years

  12. Phase 2, Part 4: CR as Per Investigator Assessment of Response According to the Lugano Criteria

    CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative.

    Time frame: up to approximately 6 years

  13. Phase 2, Part 4: DOR as Per Investigator Assessment of Response According to the Lugano Criteria

    DOR was defined as the time from the first documented CR/CMR or PR/PMR as determined by an IRC according to the Lugano criteria until the date of the first documented disease progression or death due to any cause, whichever occurred first. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

    Time frame: up to approximately 6 years

  14. Phase 2, Part 4: PFS as Per Investigator Assessment of Response According to the Lugano Criteria

    PFS was defined as the time from the date of the first dose of study treatment until the first documented disease progression as determined by an IRC according to the Lugano criteria or death due to any cause, whichever occurred first.

    Time frame: up to approximately 6 years

  15. Phase 2, Part 4: Number of Participants With Any TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose.

    Time frame: up to approximately 6 years

  16. Phase 2, Part 4: Number of Participants With Any ≥Grade 3 TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to approximately 6 years

08

Results

Posted Oct 21, 2026

Participant flow

Participant flow — Overall Study
MilestonePhase 1, Part 1, Group 1: Tafasitamab MonotherapyPhase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)Phase 1, Part 2, Group 3: Tafasitamab Plus LENPhase 1, Part 2, Group 4a: Tafasitamab Plus ParsaclisibPhase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOPPhase 2, Part 4, Group 6: Tafasitamab Plus LEN
Started6666642
Completed313250
Not completed3534142
Withdrew: Death000017
Withdrew: Withdrawal by subject000102
Withdrew: Lost to follow-up000100
Withdrew: Priority given to next treatment002000
Withdrew: Ongoing3512033

Outcome measures

PrimaryPhase 1, Parts 1 and 2; Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose.

Time frame:
up to 1066 days
Reported as:
Count of participants · Participants
Phase 1, Parts 1 and 2; Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsPhase 1, Part 1, Group 1: Tafasitamab MonotherapyPhase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)Phase 1, Part 2, Group 3: Tafasitamab Plus LENPhase 1, Part 2, Group 4a: Tafasitamab Plus ParsaclisibPhase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP
Phase 1, Parts 1 and 2; Number of Participants With Any Treatment-emergent Adverse Event (TEAE)66666
PrimaryPhase 1, Parts 1 and 2; Number of Participants With Any ≥Grade 3 TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 1066 days
Reported as:
Count of participants · Participants
Phase 1, Parts 1 and 2; Number of Participants With Any ≥Grade 3 TEAE
ParticipantsPhase 1, Part 1, Group 1: Tafasitamab MonotherapyPhase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)Phase 1, Part 2, Group 3: Tafasitamab Plus LENPhase 1, Part 2, Group 4a: Tafasitamab Plus ParsaclisibPhase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP
Phase 1, Parts 1 and 2; Number of Participants With Any ≥Grade 3 TEAE23546
PrimaryPhase 1, Part 1 and Part 2 (Groups 3, 4a, and 5); Number of Participants With Any Dose-limiting Toxicity (DLT)

A DLT was defined as the occurrence of any protocol-defined toxicity occurring up to and including Day 28 (Day 21 in Group 5 only), except those with a clear alternative explanation.

Time frame:
up to 28 days
Reported as:
Count of participants · Participants
Phase 1, Part 1 and Part 2 (Groups 3, 4a, and 5); Number of Participants With Any Dose-limiting Toxicity (DLT)
ParticipantsPhase 1, Part 1, Group 1: Tafasitamab MonotherapyPhase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)Phase 1, Part 2, Group 3: Tafasitamab Plus LENPhase 1, Part 2, Group 4a: Tafasitamab Plus ParsaclisibPhase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP
Phase 1, Part 1 and Part 2 (Groups 3, 4a, and 5); Number of Participants With Any Dose-limiting Toxicity (DLT)0—101
PrimaryPhase 2, Part 4: Objective Response (OR) as Determined by an Independent Review Committee (IRC) According to Lugano Criteria

OR=percentage of participants with a complete response/complete metabolic response (CR/CMR) or partial response/partial metabolic response (PR/PMR). CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 centimeters (cm) in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

Time frame:
up to 723 days
Reported as:
Number · percentage of participants
Phase 2, Part 4: Objective Response (OR) as Determined by an Independent Review Committee (IRC) According to Lugano Criteria
percentage of participantsPhase 2, Part 4, Group 6: Tafasitamab Plus LEN
Phase 2, Part 4: Objective Response (OR) as Determined by an Independent Review Committee (IRC) According to Lugano Criteria71.4 (57.9 to 82.6)
SecondaryPhase 1, Parts 1 and 2; Cmax of Tafasitamab

Cmax was defined as the maximum observed plasma concentration of tafasitamab. Samples were collected as follows: Groups 1, 3, and 4a: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours post-infusion (PI). Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 4, 8, 15, and 22, preinfusion; 1 hour PI. Cycles 2 and 3 Days 1, 22, preinfusion and 1 hour PI. Cycle 4 and beyond every 4 cycles (8, 12, etc.) Day 1, preinfusion. Safety follow-up/end of study visit, untimed sample. Group 2: Cycle 1 Days 1, 4, 8, and 15, preinfusion, 30 min PI. Cycles 2 and 3 Days 1 and 15, preinfusion and 30 min PI. Cycle 4-12 (every other cycle, i.e., Cycle 4, 6, 8, 12) Day 1, preinfusion and 30 min PI. Cycle 12 Day 28 and end of treatment, untimed sample. Group 5: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours PI. Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 8 and 15, preinfusion and 1 hour PI. Cycles 2 and 3-6 Day 1, preinfusion and 1 hour PI.

Time frame:
Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment

Results for this outcome have not been posted.

SecondaryPhase 1, Parts 1 and 2; Cmin of Tafasitamab

Cmin was defined as the minimum observed plasma concentration of tafasitamab. Samples were collected as follows: Groups 1, 3, and 4a: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours post-infusion (PI). Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 4, 8, 15, and 22, preinfusion; 1 hour PI. Cycles 2 and 3 Days 1, 22, preinfusion and 1 hour PI. Cycle 4 and beyond every 4 cycles (8, 12, etc.) Day 1, preinfusion. Safety follow-up/end of study visit, untimed sample. Group 2: Cycle 1 Days 1, 4, 8, and 15, preinfusion, 30 min PI. Cycles 2 and 3 Days 1 and 15, preinfusion and 30 min PI. Cycle 4-12 (every other cycle, i.e., Cycle 4, 6, 8, 12) Day 1, preinfusion and 30 min PI. Cycle 12 Day 28 and end of treatment, untimed sample. Group 5: Cycle 1 Day 1, preinfusion, immediately after tafasitamab infusion, 1 and 4 hours PI. Cycle 1 Day 2, 24 hours PI on Day 1. Cycle 1 Days 8 and 15, preinfusion and 1 hour PI. Cycles 2 and 3-6 Day 1, preinfusion and 1 hour PI.

Time frame:
Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4; Cmax of Tafasitamab

Cmax was defined as the maximum observed plasma concentration of tafasitamab.

Time frame:
Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4; Cmin of Tafasitamab

Cmin was defined as the minimum observed plasma concentration of tafasitamab.

Time frame:
Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample

Results for this outcome have not been posted.

SecondaryPhase 1, Part 2: Percentage of Participants With the Indicated Response Per Investigator Assessment of Response According to the Lugano Criteria

CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 1, Part 2: Percent Reduction in the Sum of the Products of Perpendicular Diameters for Multiple Lesions in up to 6 Target Measurable Nodes/Extranodal Sites Assessed by Computed Tomography as Per Investigator Assessment of Lugano Criteria Response

The sum of the products of the longest perpendicular diameters (SPD) was calculated by summing the products of the two longest perpendicular diameters for each target lesion or any extranodal lesion. Percent reduction in SPD from baseline in up to 6 target measurable nodes and extranodal sites assessed by computed tomography as per investigator assessment of response according to the Lugano criteria was calculated per assessment, and the highest reduction was analyzed.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: Complete Response (CR) as Determined by an IRC According to Lugano Criteria

CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: Kaplan-Meier Estimate of Duration of Response (DOR) as Determined by an IRC According to Lugano Criteria

DOR was defined as the time from the first documented CR/CMR or PR/PMR as determined by an IRC according to the Lugano criteria until the date of the first documented disease progression or death due to any cause, whichever occurred first. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: Kaplan-Meier Estimate of Progression-free Survival (PFS) as Determined by an IRC

PFS was defined as the time from the date of the first dose of study treatment until the first documented disease progression as determined by an IRC according to the Lugano criteria or death due to any cause, whichever occurred first. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: Kaplan-Meier Estimate of Overall Survival

Overall survival was defined as defined as the time from the first dose of study treatment until death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: OR as as Per Investigator Assessment of Response According to the Lugano Criteria

OR=percentage of participants with a CR/CMR or PR/PMR. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: CR as Per Investigator Assessment of Response According to the Lugano Criteria

CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: DOR as Per Investigator Assessment of Response According to the Lugano Criteria

DOR was defined as the time from the first documented CR/CMR or PR/PMR as determined by an IRC according to the Lugano criteria until the date of the first documented disease progression or death due to any cause, whichever occurred first. CR: (1) target nodes/nodal masses of lymph nodes/extralymphatic sites regressed to ≤1.5 cm in the longest dimension transverse diameter of lesion (LDi); (2) absence of non-measured lesions; (3) organ enlargement regressed to normal; (4) no new lesions; (5) normal bone marrow morphology; if indeterminate, immunohistochemistry negative. PR: (1) lymph nodes/extralymphatic sites: ≥50% decrease in the sum of the product of perpendicular diameters for multiple lesions of up to 6 target measurable nodes/extranodal sites; (2) absent/regressed non-measured lesions, no increase; (3) organ enlargement; spleen regressed by \>50% in length beyond normal; (4) no new lesions.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: PFS as Per Investigator Assessment of Response According to the Lugano Criteria

PFS was defined as the time from the date of the first dose of study treatment until the first documented disease progression as determined by an IRC according to the Lugano criteria or death due to any cause, whichever occurred first.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: Number of Participants With Any TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

SecondaryPhase 2, Part 4: Number of Participants With Any ≥Grade 3 TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any new AE/worsening of an event from the first dose to 90 days (30 days until Amendment 3) after the last dose. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to approximately 6 years

Results for this outcome have not been posted.

Adverse events

Collected over up to approximately 4.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1, Part 1, Group 1: Tafasitamab monotherapyPhase 1, Part 1, Group 1: Tafasitamab Monotherapy0/6 (0%)0/6 (0%)6/6 (100%)
Phase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)0/6 (0%)0/6 (0%)6/6 (100%)
Phase 1, Part 2, Group 3: Tafasitamab Plus LEN0/6 (0%)2/6 (33.3%)6/6 (100%)
Phase 1, Part 2, Group 4a: Tafasitamab Plus Parsaclisib0/6 (0%)1/6 (16.7%)6/6 (100%)
Phase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOP1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Phase 2, Part 4, Group 6: Tafasitamab Plus LEN7/42 (16.7%)8/42 (19%)40/42 (95.2%)
Total8/72 (11.1%)12/72 (16.7%)70/72 (97.2%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPhase 1, Part 1, Group 1: Tafasitamab monotherapyPhase 1, Part 1, Group 1: Tafasitamab MonotherapyPhase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)Phase 1, Part 2, Group 3: Tafasitamab Plus LENPhase 1, Part 2, Group 4a: Tafasitamab Plus ParsaclisibPhase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOPPhase 2, Part 4, Group 6: Tafasitamab Plus LENTotal
COVID-19Infections and infestations0/60/61/60/60/62/423/72
Depressed level of consciousnessNervous system disorders0/60/60/60/61/60/421/72
DiarrhoeaGastrointestinal disorders0/60/60/61/60/60/421/72
Liver disorderHepatobiliary disorders0/60/61/60/60/60/421/72
Optic ischaemic neuropathyEye disorders0/60/60/60/61/60/421/72
AnaemiaBlood and lymphatic system disorders0/60/60/60/60/61/421/72
Atrial fibrillationCardiac disorders0/60/60/60/60/61/421/72
CholelithiasisHepatobiliary disorders0/60/60/60/60/61/421/72
Herpes zosterInfections and infestations0/60/60/60/60/61/421/72
MalaiseGeneral disorders0/60/60/60/60/61/421/72
Most frequent other events
Showing 10 of 96
Most frequent other events
EventPhase 1, Part 1, Group 1: Tafasitamab monotherapyPhase 1, Part 1, Group 1: Tafasitamab MonotherapyPhase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)Phase 1, Part 2, Group 3: Tafasitamab Plus LENPhase 1, Part 2, Group 4a: Tafasitamab Plus ParsaclisibPhase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOPPhase 2, Part 4, Group 6: Tafasitamab Plus LENTotal
White blood cell count decreasedInvestigations1/62/62/61/66/62/4214/72
AnaemiaBlood and lymphatic system disorders0/61/62/61/65/64/4213/72
Neutrophil count decreasedInvestigations0/63/63/63/65/611/4225/72
DiarrhoeaGastrointestinal disorders0/61/63/64/60/616/4224/72
AlopeciaSkin and subcutaneous tissue disorders0/60/60/60/63/60/423/72
Back painMusculoskeletal and connective tissue disorders0/60/60/60/63/62/425/72
ConstipationGastrointestinal disorders1/60/61/60/63/612/4217/72
Decreased appetiteMetabolism and nutrition disorders0/61/63/60/60/64/428/72
Febrile neutropeniaBlood and lymphatic system disorders0/60/60/60/63/60/423/72
Lymphocyte count decreasedInvestigations1/61/61/61/63/62/429/72

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1, Part 1, Group 1: Tafasitamab MonotherapyPhase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)Phase 1, Part 2, Group 3: Tafasitamab Plus LENPhase 1, Part 2, Group 4a: Tafasitamab Plus ParsaclisibPhase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOPPhase 2, Part 4, Group 6: Tafasitamab Plus LENTotal
Mean72.0 ± 4.9879.0 ± 4.4773.2 ± 7.4768.5 ± 9.8166.8 ± 5.4272.5 ± 6.3872.2 ± 6.86
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1, Part 1, Group 1: Tafasitamab MonotherapyPhase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)Phase 1, Part 2, Group 3: Tafasitamab Plus LENPhase 1, Part 2, Group 4a: Tafasitamab Plus ParsaclisibPhase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOPPhase 2, Part 4, Group 6: Tafasitamab Plus LENTotal
Female443542343
Male223121929
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1, Part 1, Group 1: Tafasitamab MonotherapyPhase 1, Part 2, Group 2: Tafasitamab Plus Lenalidomide (LEN)Phase 1, Part 2, Group 3: Tafasitamab Plus LENPhase 1, Part 2, Group 4a: Tafasitamab Plus ParsaclisibPhase 1, Part 2, Group 5: Tafasitamab Plus LEN Plus R-CHOPPhase 2, Part 4, Group 6: Tafasitamab Plus LENTotal
Asian666664272
09

Study locations

23 sites
10

References and documents

Publications

  • Izutsu K, Fukuhara N, Yuda J, Suehiro Y, Kusumoto S, Casadebaig ML, Suzukawa K, Fukushima K. Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study. Cancer Sci. 2026 Apr;117(4):1093-1105. doi: 10.1111/cas.70306. Epub 2026 Jan 21. PubMed 41563911 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2025, 54 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 54 months is below that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 9, 2020
StartActual
Dec 15, 2020
Primary completionActual
Jul 1, 2025
CompletionEst.
Dec 31, 2026
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Primary outcomes
1 edited, 3 added, 1 removed
What changed in the outcomes
  • EditedPartPhase 1,2 Parts 1 and 3 :2; Number of Participants With Any Treatment Emergent-emergent Adverse EventsEvent (TEAE'S)Time frame: Approximately 2 years → up to 1066 days
  • AddedPhase 1, Parts 1 and 2; Number of Participants With Any ≥Grade 3 TEAETime frame: up to 1066 days
  • AddedPhase 1, Part 1 and Part 2 (Groups 3, 4a, and 5); Number of Participants With Any Dose-limiting Toxicity (DLT)Time frame: up to 28 days
  • AddedPhase 2, Part 4: Objective Response (OR) as Determined by an Independent Review Committee (IRC) According to Lugano CriteriaTime frame: up to 723 days
  • RemovedPart 4: Objective ResponseTime frame: Approximately 27 months
Oct 21, 2026
Documents
Secondary outcomes
3 edited, 13 added, 5 removed
What changed in the outcomes
  • EditedPartPhase 1,2, 3 Parts 1 and 4 :2; Cmax of tafasitamabTafasitamabTime frame: Approximately 27 months → Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment
  • EditedPartPhase 1, 2, 3Parts 1 and 4:2; Cmin of tafasitamabTafasitamabTime frame: Approximately 27 months → Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment
  • EditedPhase 2, Part 4: Kaplan-Meier Estimate of Overall SurvivalTime frame: Approximately 27 months → up to approximately 6 years
  • AddedPhase 2, Part 4; Cmax of TafasitamabTime frame: Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample
  • AddedPhase 2, Part 4; Cmin of TafasitamabTime frame: Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample
  • AddedPhase 1, Part 2: Percentage of Participants With the Indicated Response Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
  • AddedPhase 1, Part 2: Percent Reduction in the Sum of the Products of Perpendicular Diameters for Multiple Lesions in up to 6 Target Measurable Nodes/Extranodal Sites Assessed by Computed Tomography as Per Investigator Assessment of Lugano Criteria ResponseTime frame: up to approximately 6 years
  • AddedPhase 2, Part 4: Complete Response (CR) as Determined by an IRC According to Lugano CriteriaTime frame: up to approximately 6 years
  • AddedPhase 2, Part 4: Kaplan-Meier Estimate of Duration of Response (DOR) as Determined by an IRC According to Lugano CriteriaTime frame: up to approximately 6 years
  • AddedPhase 2, Part 4: Kaplan-Meier Estimate of Progression-free Survival (PFS) as Determined by an IRCTime frame: up to approximately 6 years
  • AddedPhase 2, Part 4: OR as as Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
  • AddedPhase 2, Part 4: CR as Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
  • AddedPhase 2, Part 4: DOR as Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
  • AddedPhase 2, Part 4: PFS as Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
  • AddedPhase 2, Part 4: Number of Participants With Any TEAETime frame: up to approximately 6 years
  • AddedPhase 2, Part 4: Number of Participants With Any ≥Grade 3 TEAETime frame: up to approximately 6 years
  • RemovedPart 4: Complete ResponseTime frame: Approximately 27 months
  • RemovedPart 4: Duration of ResponseTime frame: Approximately 27 months
  • RemovedPart 4: Progression-Free SurvivalTime frame: Approximately 27 months
  • RemovedPart 4: Overall Response RateTime frame: Approximately 27 months
  • RemovedPart 4: Treatment Emergent Adverse Events (TEAE'S)Time frame: Approximately 2 years
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Primary outcomes 1 edited, 3 added, 1 removed
    What changed in the outcomes
    • EditedPartPhase 1,2 Parts 1 and 3 :2; Number of Participants With Any Treatment Emergent-emergent Adverse EventsEvent (TEAE'S)Time frame: Approximately 2 years → up to 1066 days
    • AddedPhase 1, Parts 1 and 2; Number of Participants With Any ≥Grade 3 TEAETime frame: up to 1066 days
    • AddedPhase 1, Part 1 and Part 2 (Groups 3, 4a, and 5); Number of Participants With Any Dose-limiting Toxicity (DLT)Time frame: up to 28 days
    • AddedPhase 2, Part 4: Objective Response (OR) as Determined by an Independent Review Committee (IRC) According to Lugano CriteriaTime frame: up to 723 days
    • RemovedPart 4: Objective ResponseTime frame: Approximately 27 months
    Secondary outcomes 3 edited, 13 added, 5 removed
    What changed in the outcomes
    • EditedPartPhase 1,2, 3 Parts 1 and 4 :2; Cmax of tafasitamabTafasitamabTime frame: Approximately 27 months → Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment
    • EditedPartPhase 1, 2, 3Parts 1 and 4:2; Cmin of tafasitamabTafasitamabTime frame: Approximately 27 months → Cycle 1 Days 1, 4, 8, 15, 22; Cycles 2 and 3 Days 1 and 22; Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1; End of Treatment
    • EditedPhase 2, Part 4: Kaplan-Meier Estimate of Overall SurvivalTime frame: Approximately 27 months → up to approximately 6 years
    • AddedPhase 2, Part 4; Cmax of TafasitamabTime frame: Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample
    • AddedPhase 2, Part 4; Cmin of TafasitamabTime frame: Cycle 1 Days 1, 4, and 15, preinfusion and 1 hour post-infusion. Cycles 2 and 3 Days 1 and 15, preinfusion and 1 hour post-infusion. Cycle 4 and every 4 cycles thereafter (Cycles 8, 12, etc.) Day 1, preinfusion. End of treatment, untimed sample
    • AddedPhase 1, Part 2: Percentage of Participants With the Indicated Response Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
    • AddedPhase 1, Part 2: Percent Reduction in the Sum of the Products of Perpendicular Diameters for Multiple Lesions in up to 6 Target Measurable Nodes/Extranodal Sites Assessed by Computed Tomography as Per Investigator Assessment of Lugano Criteria ResponseTime frame: up to approximately 6 years
    • AddedPhase 2, Part 4: Complete Response (CR) as Determined by an IRC According to Lugano CriteriaTime frame: up to approximately 6 years
    • AddedPhase 2, Part 4: Kaplan-Meier Estimate of Duration of Response (DOR) as Determined by an IRC According to Lugano CriteriaTime frame: up to approximately 6 years
    • AddedPhase 2, Part 4: Kaplan-Meier Estimate of Progression-free Survival (PFS) as Determined by an IRCTime frame: up to approximately 6 years
    • AddedPhase 2, Part 4: OR as as Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
    • AddedPhase 2, Part 4: CR as Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
    • AddedPhase 2, Part 4: DOR as Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
    • AddedPhase 2, Part 4: PFS as Per Investigator Assessment of Response According to the Lugano CriteriaTime frame: up to approximately 6 years
    • AddedPhase 2, Part 4: Number of Participants With Any TEAETime frame: up to approximately 6 years
    • AddedPhase 2, Part 4: Number of Participants With Any ≥Grade 3 TEAETime frame: up to approximately 6 years
    • RemovedPart 4: Complete ResponseTime frame: Approximately 27 months
    • RemovedPart 4: Duration of ResponseTime frame: Approximately 27 months
    • RemovedPart 4: Progression-Free SurvivalTime frame: Approximately 27 months
    • RemovedPart 4: Overall Response RateTime frame: Approximately 27 months
    • RemovedPart 4: Treatment Emergent Adverse Events (TEAE'S)Time frame: Approximately 2 years
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT04661007
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Dec 15, 2020
Primary completion
Jul 1, 2025
Completion
Dec 31, 2026 (estimated)
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafasitamab

Start the discussion